130369-36-7

Basic information

• Product Name: BENZYL 3-OXOCYCLOBUTYLCARBAMATE
• Synonyms: BENZYL 3-OXOCYCLOBUTYLCARBAMATE;(3-Oxo-cyclobutyl)-carbamic acid benzyl ester;N-(Benzyloxycarbonyl)-3-amino-1-cyclobutanone;(3-Oxocyclobutyl)carbamic acid phenylmethyl ester;benzyl N-(3-oxocyclobutyl)carbamate;Carbamic acid, N-(3-oxocyclobutyl)-, phenylmethyl ester;3-Z-amino-cyclobutanone, 98%
• CAS NO: 130369-36-7
• Molecular Formula: C₁₂H₁₃NO₃
• Molecular Weight: 219.239
• EINECS: 1533716-785-6
• Mol File: 130369-36-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 403.3 °C at 760 mmHg
• Flash Point: 197.7 °C
• Appearance: White crystalline powder
• Density: 1.22
• Vapor Pressure: 1.03E-06mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: 2-8°C
• PKA: 11.39±0.20(Predicted)
• CAS DataBase Reference: BENZYL 3-OXOCYCLOBUTYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL 3-OXOCYCLOBUTYLCARBAMATE(130369-36-7)
• EPA Substance Registry System: BENZYL 3-OXOCYCLOBUTYLCARBAMATE(130369-36-7)

Safety Data

• Hazardous Substances Data: 130369-36-7(Hazardous Substances Data)

Usage

Uses

Benzyl 3-Oxocyclobutylcarbamate is used in process for preparation of abrocitinib.

InChI:InChI=1/C12H13NO3/c14-11-6-10(7-11)13-12(15)16-8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,13,15)

Upstream product

• 96-50-4 2-thiazolylamine 
• 75-77-4 chloro-trimethyl-silane 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 100-51-6 benzyl alcohol 

Downstream Products

• 939399-53-8 benzyl (3,3-difluorocyclobutyl)carbamate 
• 1443928-67-3 benzyl (3-(hydroxyimino)cyclobutyl)carbamate 
• 1443928-60-6 C₁₆H₂₂N₂O₃S 
• 1609978-79-1 trans-3-{[(benzyloxy)carbonyl]amino}cyclobutyl trans-4-[(1R)-1-(6-{[4-(difluoromethyl)pyridin-2-yl]amino}-4-methyl-2,3'-bipyridin-6'-yl)-1-hydroxyethyl]cyclohexanecarboxylate 
• 305859-68-1 (R,S)-4-benzyloxycarbonylamino-4,5-dihydro-2(3H)-furanone 
• 87219-29-2 benzyl (3S)-5-oxotetrahydro-3-furanylcarbamate 
• 118399-28-3 (R)-4-benzyloxycarbonylamino-4,5-dihydro-2(3H)-furanone 
• 1201825-73-1 benzyl [cis-3-(methylamino)cyclobutyl]carbamate 

Relevant articles and documents

Development of a Nitrene-Type Rearrangement for the Commercial Route of the JAK1 Inhibitor Abrocitinib

The development of a commercial route toward the JAK1 inhibitor abrocitinib is described. The application of a late-stage Lossen rearrangement provided the desired cis-diaminocyclobutane, which was subsequently sulfonylated using a novel water-tolerable triazole sulfonylating reagent to provide the active pharmaceutical ingredient.

PROCESS FOR PREPARATION OF ABROCITINIB

The present invention relates to crystalline abrocitinib characterized by X-ray powder diffraction (XRPD) spectrum having peak reflections at about 12.9, 14.7, 19.4, 23.2 and 25.2 ±0.2 degrees 2 theta, and process for its preparation. The present invention relates to amorphous solid dispersion comprising abrocitinib or salt thereof together with at least one pharmaceutically acceptable carrier and process for its preparation.

PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS

The present invention provides compounds of Formula (I), which are prodrugs of trans-4-[(1R)-(6-{[4-(difluoromethyl)pyridin-2-yl]amino}-4-methyl-2,3'-bipyridin-6'-yl)-1-hydroxyethyl]cyclohexanecarboxylic acid, a potent inhibitor of Syk. The compounds are useful in the treatment and prevention of diseases mediated by the enzyme, such as asthma, COPD, rheumatoid arthritis and cancer.